FDA gives nod to Aurobindo Pharma 's Esomol Hydrochloride Injection
USFDA has given a green signal to Aurobindo Pharma manufacture and market Esmolol Hydrochloride Injection for the short-term treatment of tachycardia and hypertensionAurobindo Pharma has received an approval from the US Food and Drug Administration to manufacture and market Esmolol Hydrochloride Injection. The treatment through the injection is indicated for the short-term treatment of...
Login or Register to read the full article
USFDA has given a green signal to Aurobindo Pharma manufacture and market Esmolol Hydrochloride Injection for the short-term treatment of tachycardia and hypertension
Aurobindo Pharma has received an approval from the US Food and Drug Administration to manufacture and market Esmolol Hydrochloride Injection. The treatment through the injection is indicated for the short-term treatment of tachycardia and hypertension that occur during induction and tracheal intubation, during surgery, on emergence from anaesthesia and in the postoperative period.
According to a press release, Esmolol Hydrochloride Injection, 100mg/10mL (10mg/mL) is bioequivalent and therapeutically equivalent to the reference listed drug product (RLD) Brevibloc Injection, 10mg/mL of Baxter Healthcare Corporation.
Aurobindo pharma now has 13 ANDAs (represented by 10 product classes) approved out of Unit IV formulation facility in Hyderabad for manufacturing general injectable products and will be marketed and sold by Aurobindo's wholly-owned subsidiary AuroMedics Pharma LLC, the statement added.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd